Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about NOVARTIS
11:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
11:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15DJNOVARTIS : Oncology CEO Bruno Strigini to Retire
12/15 NOVARTIS : announces Oncology head to retire
12/14 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
12/14 ONCY VENT : Result of Oncology Ventures Drug Response Prediction for TKI drug fr..
12/13 Aduro discontinues development of CRS-207
12/12 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx in pat..
12/12 NOVARTIS : Sandoz announces new Phase I data showing proposed biosimilar pegfilg..
12/11 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 ROCHE, NOVARTIS' ITALIAN HEADS RISK : sources
More most relevant news
All news about NOVARTIS
11:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
11:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
09:18a PFIZER : weighs `strategic options` for newly FDA-approved Remicade biosim, its ..
12/15 NOVARTIS : ACC Urges for Protection of Privilege in Johns Hopkins Univ. V Alcon ..
12/15 NOVARTIS : NAD Recommends Alcon Laboratories Discontinue Certain Claims for 'Cle..
12/15 NOVARTIS : Result of Oncology Ventures Drug Response Prediction for TKI drug fro..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15DJNOVARTIS : Oncology CEO Bruno Strigini to Retire
12/15 NOVARTIS : announces Oncology head to retire
12/14 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx® in pa..
More news
Sector news : Pharmaceuticals - NEC
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15DJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
12/15DJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12/15 Wall Street falls as investors fret about tax bill passage
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:51a Stocks to watch next week
12/15 UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
12/15 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Did ASH Just Change The Juno Best In Class Thesis?
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 505 M
Debt 2017 17 812 M
Yield 2017 3,36%
P/E ratio 2017 24,57
P/E ratio 2018 21,41
EV / Sales 2017 4,87x
EV / Sales 2018 4,66x
Capitalization 222 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.09%221 731
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386
AMGEN21.32%128 515